News Related to Ornithine Transcarbamylase (OTC) Deficiency

Related coverage linked through entity extraction aliases.

Arcturus Therapeutics Plans 12-Week Phase 2 Cystic Fibrosis Trial After Positive Safety Data

Mar 12, 2026

Arcturus Therapeutics completed three 28-day inhaled mRNA cohorts for cystic fibrosis that were well-tolerated and showed early biological signals. The company is preparing a 12-week Phase 2 study with tightened eligibility criteria and expanded enrollment into Europe and the Middle East.

Arcturus Therapeutics Schedules Q4 and Fiscal Year 2025 Earnings Release for March 3

Feb 18, 2026

Arcturus Therapeutics will release fourth quarter and fiscal year 2025 financial results after market close on March 3, 2026, followed by a conference call at 4:30 p.m. Eastern Time.